Home Featured Page 211

Featured

Latest

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Red Light Holland to Collaborate with Advocacy Group, Psychedelic Medicine Alliance...

Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations...

BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics...

Entheon Biomedical Corp. Files Preliminary Shelf Prospectus

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy...

MindMed Enrolls First Participant in a Study of its Session Monitoring...

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

PT285 – Andrew Penn, NP – The Need for Nurses in...

Psychedelic Research Bulletin: December 2021

Nova Mentis Provides Corporate Update – 2022 Planned Catalysts

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

The Best Psychedelic Education Does Not Look Psychedelic

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

Pα+ Psychedelic Bulletin #230: Pharma Ramps Up Ad Spend on Psychedelic Keywords; ARPA-H’s Ibogaine Funding; Psychedelics in Medicaid?

A Closer Look at Definium’s Phase 3 LSD for GAD Readout

Red Light Holland to Collaborate with Advocacy Group, Psychedelic Medicine Alliance...

Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations...

BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics...

Entheon Biomedical Corp. Files Preliminary Shelf Prospectus

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy...

MindMed Enrolls First Participant in a Study of its Session Monitoring...

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

PT285 – Andrew Penn, NP – The Need for Nurses in...

Psychedelic Research Bulletin: December 2021

Nova Mentis Provides Corporate Update – 2022 Planned Catalysts

EDITOR PICKS

Two New Zealand Psychiatrists Approved to Prescribe MDMA for PTSD

Pα+ Library: Psychedelic REMS

The Best Psychedelic Education Does Not Look Psychedelic

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY